Dr. John Cush RheumNow
2 years ago
Increasing Incidence of Morphea
A large EMR cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on the increasing prevalence of morphea.
https://t.co/ISqv4y0Pkp https://t.co/KM3gbt2iWd
Dr. John Cush RheumNow
2 years ago
Exploratory analysis from an academic center showed SLE pts w/ higher odds of positive ANA vs. other ANA-asso diseases (OR 2.10). Over 20 yrs, ANA titers are more dynamic than expected; & average titers being higher in early disease and decreasing over time.… https://t.co/iQXN0nPSIG https://t.co/viMTGen34K
Dr. John Cush RheumNow
2 years ago
Pipeline drugs and trials intended for Interstitial Lung Disease - including studies with nintedinib, Efzofitimod, BI 1015550, AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells...Riociguat, Treprostinil and more https://t.co/fpMjjubPVx https://t.co/ketFP0N9jk
Dr. John Cush RheumNow
2 years ago
Yes you can space out Guselkumab injx in controlled Psoriasis. Phase 3b RCT of 149 GUS pts w/ PASI <4 were cont on GUS q8 wks or spaced to q16wks. Noninferiority was shown w/ maintenance of "super-responders" in > 90% w/ both https://t.co/4Y9quetoJn https://t.co/zP9ywFKpvY
Dr. John Cush RheumNow
2 years ago
Retrospective analysis of 63K Alopecia areata pts shows a higher risk of developing psychiatric (aHR 1.3) & autoimmune Dz (aHR 2.7), including SLE (aHR 5.7), atopic dermatitis (4.3), vitiligo (3.8), Sjogrens (3.7), Morphea (3.6), PsO (2.8), RA (1.8) https://t.co/gnEm9TsyoV https://t.co/XWA98sbRLp
Dr. John Cush RheumNow
2 years ago
PEDIALUP registry includes 138 childhood-onset SLE (cSLE) pts.w/ 15.4 yrs median F/U, showed signif increase in SLICC-damage index (DI) scores. 34% cSLE pts had active dz w/ SLEDAI ≥6. sub-Saharan African ethnicity 7-fold incr risk of active cSLE https://t.co/iLz7DMTQuf https://t.co/tJpEvst7p4
Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
Dr. John Cush RheumNow
2 years ago
40 postmenopausal F Rx w/ Blackcurrant (BC) vs PBO. @6 mos BC lowered IL-1β (P .056) & RANKL (P .052) & BMD inversely correlated w/ RANKL change. BC bone protective may also be through enhancing gut microbial balance https://t.co/wy9VR3fwvJ https://t.co/cRCjSb5XDQ
How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement? A trial of early use of mycophenolate mofetil (MMF), in addition to prednisone and hydroxychloroquine, decreased severe flares and the development of renal involvement.
Dr. John Cush RheumNow
2 years ago
IMPORTANT: Cost effectiveness analysis of the TREAT EARLIER RCT shows 88% probability that 1 yr of MTX in 236 pts w/ clinically suspect arthralgia was cost-effective. Results shows MTX Rx increased quality adjusted life years & reduced costs https://t.co/1BVxs77vo8 https://t.co/uQSQL5Eww9
Dr. John Cush RheumNow
2 years ago
Study of 115 systemic sclerosis (SSc) pts followed 4 yrs. modified Rodnan skin score @ 4 yrs correlated w/ baseline mRSS & finger-to-palm distance (length from the distal tip of the fourth finger to the distal palmar crease) https://t.co/TwMy5Mh68r https://t.co/4qhhBS9yOH
Julia Simard, ScD RheumEpi
2 years ago
Study extended - People with #lupus #SLE: We'd love to hear about your experiences. Either use the link below or scan the QR code with another device. https://t.co/gbmn8PWbwd https://t.co/MHLbDdCGbf
Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.
Dr. John Cush RheumNow
2 years ago
Cancer presenting as Inflammatory low back pain? 34 Cases presenting as SpA over 10 yrs often w/ higher ESR/CRP/LDH levels. CA included myeloma, leukemia, lymphoma, CA of breast/lung/prostate & bone tumors. https://t.co/YYKYx39tbD https://t.co/m9uCbJBsnU
